A snapshot of Europe’s MedTech momentum

MedTech Europe’s Facts & Figures 2025 report offers a clear view of where the industry stands—and where it’s heading.

With €170 billion in market value, over 38,000 companies (90% of them SMEs), and 930,000 direct employees, the medical technology sector is one of Europe’s most dynamic and vital industries. But beyond the numbers, this year’s report tells a deeper story: Europe’s MedTech ecosystem is evolving into a design-driven, data-enabled, and digitally integrated network that’s reshaping the future of care.

For design consultancies like Maddison, the implications are clear. Successful innovation in 2025 and beyond will depend on bridging human-centred design with regulatory precision, manufacturing scalability, and system-level integration.

1. A sector built on innovation and design agility

Europe’s MedTech industry continues to outperform other technology sectors in innovation activity.

In 2024, the European Patent Office recorded 15,701 medical technology patent applications, far exceeding biotechnology (8,479) and pharmaceuticals (8,359). Even more telling: 70% of medtech patents were granted, compared with just 36% in pharma.

That ratio signals something fundamental about design in MedTech it’s fast, iterative, and commercially focused. Medical technologies typically have 18–24-month lifecycles, meaning constant product refinement and design renewal are essential.

At Maddison, we’ve long recognised that the ability to iterate safely under ISO 13485 is a competitive advantage.

Our agile design framework, combining user testing, design for manufacture, and compliance-led documentation, mirrors the industry’s short innovation cycles while maintaining regulatory readiness.

2. Regulation: design’s constant companion

The report underlines how the Medical Device Regulation (EU 2017/745) and In Vitro Diagnostic Regulation (EU 2017/746) continue to reshape the landscape. Every product, from plasters to pacemakers, is now classified under a risk-based system that determines both design control intensity and post-market obligations.

For design teams, that means regulatory literacy is no longer optional. It’s part of the creative process.

At Maddison, we integrate MDR and IVDR principles from the first sketch. Our approach ensures human-factors documentation, usability validation, and risk management are embedded, not retrofitted. That gives our clients smoother paths through technical file compilation and notified body review. 

Design compliance is design excellence. The best innovations aren’t just brilliant, they’re built to pass.

3. Digital health comes of age

Perhaps the strongest signal in this year’s report is that digital health is now a core pillar, not a peripheral trend. Germany’s DiGA reimbursement pathway, the world’s first for digital therapeutics, has now reimbursed 59 solutions with over one million prescriptions issued. France and Belgium have followed with national frameworks of their own, and 85% of DiGA-prescribed solutions are actively used by patients. This momentum reflects a decisive shift: Europe’s health systems are embracing software as therapy.

For designers, this demands fluency in digital ecosystems, user experience, and clinical validation. The interface is now the treatment.

At Maddison, we see this first-hand in projects spanning connected diagnostics, wearables, and rehabilitation platforms. Success depends on aligning clinical rigour with consumer-grade usability, a combination that turns “digital health” into “digital care”.

4. Employment and economic value: design as an economic driver

With 930,000 direct employees and value added per employee of €183,000, the MedTech sector isn’t just medically vital, it’s economically strategic. Germany leads in total employment (212,000), followed by Italy and the UK, but Ireland and Switzerland rank highest per capita, reflecting their concentration of high-value manufacturing and design. The report highlights that small and medium enterprises (SMEs) form the backbone of Europe’s MedTech sector, around 90% of companies employ fewer than 50 people. This structure creates both challenge and opportunity: innovation thrives in small teams, but scaling it requires design partners who understand regulatory, industrial, and commercial integration.

That’s where Maddison fits.

For over 40 years we’ve helped SMEs and corporate innovators translate concept IP into manufacturable, compliant, and user-centred products that scale internationally.

5. Spending and market dynamics: design efficiency under pressure

Europe spends roughly 10% of GDP on healthcare, of which less than 1% of GDP, around €319 per capita, is allocated to medical technologies. Despite its modest share of spending, the sector delivers disproportionate value through prevention, diagnosis, and early intervention. This creates a powerful design imperative: MedTech products must deliver measurable outcomes with ever-greater efficiency. As health systems shift toward value-based care, design must quantify value, not just aesthetic or ergonomic appeal but lifecycle cost, data utility, and impact on clinical pathways.

Maddison’s design philosophy: “Design That Means Business” reflects precisely this.

We build the business case into the prototype, ensuring innovation doesn’t just function but proves its value to commissioners, payers, and users alike.

6. Europe’s market footprint: diverse, complex, opportunity-rich

The European MedTech market, at €170 billion, now represents 26.4% of the global device market, second only to the US. The top five markets; Germany, France, the UK, Italy and Spain account for 67% of total European value. Growth has averaged 6% annually over the past decade, a testament to resilience even through economic cycles and pandemic disruption. In-vitro diagnostics (IVDs) surged by 40% during COVID-19 but are now stabilising at a 4–5% growth trend.

For design teams, this diversity means one size never fits all. Each market brings distinct reimbursement systems, user expectations, and cultural contexts, from Germany’s precision-driven hospitals to Italy’s community-based care model.

At Maddison, we design across these differences, developing products, interfaces, and packaging that resonate with local users while complying with pan-European regulation.

7. Trade, manufacturing and the design geography of MedTech

Europe remains a net exporter of medical devices, with a €5 billion trade surplus in 2024. Ireland, Germany, the Netherlands and Switzerland dominate exports, while the US and China remain Europe’s top trading partners. However, the report notes a growing influx of imports from extra-European markets, especially China and Mexico, signalling competitive pressure on manufacturing costs and supply-chain resilience.

For European design consultancies, this creates both risk and opportunity. To stay competitive, Europe must pair design excellence with advanced manufacturing efficiency. Design must anticipate manufacturability early, reduce part counts, and enable localised assembly to mitigate supply disruptions.

At Maddison, we integrate Design for Manufacture and Assembly (DFMA) principles at concept stage, balancing precision engineering with supply-chain realism.

8. Digital convergence: the new design frontier

Across the report’s sections—innovation, regulation, digital health—one pattern stands out: digital convergence. Whether through connected diagnostics, AI-assisted analysis, or home-based monitoring, MedTech is moving from discrete devices to continuous, data-rich ecosystems. This requires a redefinition of what “device design” means. It’s no longer just physical ergonomics or mechanical innovation—it’s also data visualisation, user interface clarity, and system interoperability.

Maddison’s interdisciplinary design team—spanning industrial design, UX, engineering and regulatory documentation—was built precisely for this convergence. We help companies design platforms, not just products, integrating hardware, software, and human experience into coherent, compliant systems.

9. The SME edge: grassroots innovation that shapes the industry

The report reminds us that SMEs are the heart of European MedTech innovation. They move fast, iterate boldly, and drive new categories—from point-of-care diagnostics to assistive robotics and digital rehabilitation. Yet their success depends on access to structured design and development pathways—exactly where expert partners like Maddison add value. By guiding smaller teams through feasibility, usability engineering, and ISO-compliant documentation, we help turn innovation into investable reality.

This is why design consultancies matter more than ever: we’re the bridge between raw innovation and market readiness.

10. The road ahead: design as Europe’s competitive advantage

Europe’s MedTech sector faces global competition, regulatory tightening, and rising costs, but its real differentiator is design quality. From human-factors integration to aesthetic clarity and ethical UX, design is where technology meets trust.

As MedTech Europe’s Facts & Figures shows, the continent’s innovation engine is robust, but sustaining that momentum depends on turning invention into adoption. That is the role design plays: translating complexity into clarity, and potential into performance.

At Maddison, we believe design is Europe’s competitive advantage, and we’re proud to be part of that story.

References

Based on data from MedTech Europe, Facts & Figures 2025 (MedTech Europe, 2025) and supporting sources: EPO Patent Index 2024, Eurostat 2025, EFPIA 2025, Fitch Solutions 2025, WHO Global Health Expenditure Database 2019.